Evoke Pharma (EVOK) said Monday that a study showed that its nasal spray, Gimoti, used to treat patients with diabetic gastroparesis who were concurrently using GLP-1, showed reduced healthcare resource utilization compared with oral Metoclopramide.
The study showed that all-cause emergency department visits decreased by 55%, while diabetic gastroparesis-related emergency department visits reduced by 28% in patients with a prior GLP-1 history, the company said.
It added that all-cause and diabetic gastroparesis-related emergency departments were 91% and 89% lower, respectively, in patients taking GLP-1.
Shares of the drug developer more than doubled in premarket activity.
Price: 11.50, Change: +6.37, Percent Change: +124.17
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.